Liminal BioSciences to present PAH data at AHA meeting

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) plans to present two scientific posters with new preclinical development in the treatment of pulmonary arterial hypertension (PAH) at the American Heart Association annual meeting on Nov.16-19 in Philadelphia.

“In collaboration with Montreal Heart Institute, we are pleased to present data showing significant activity of PBI-4050 in PAH, and also in combination with Valsartan in group 2 PH associated with left heart disease, with currently no therapy approved for prevention or treatment of group 2 PH,” CEO, Kenneth Galbraith, said in a statement.